Patient Safety Technologies Reports Second Quart...(8) Realized gain (loss) assets ...),Health

Date:8/6/2009

8) Realized gain (loss) assets held for sale, net - - - (25) Unrealized loss on assets held for sale, net - - - (65) --- --- --- --- Total other income (expense) (2,375) (256) (4,307) (433) ------ ---- ------ ---- Loss from operations before income taxes (3,966) (2,432) (7,528) (4,033) Income tax provision 31 32 65 65 -- -- -- -- Net income (loss) (3,935) (2,400) (7,463) (3,968) Preferred dividends (19) (19) (38) (38) --- --- --- --- Net loss applicable to common shareholders $(3,954) $(2,419) $(7,501) $(4,006) ======= ======= ======= ======= Net loss per common share - basic and diluted $(0.23) $(0.19) $(0.44) $(0.32) ====== ====== ====== ====== Weighted average common shares outstanding: Basic and diluted 17,198 13,054 17,198 12,567 ====== ====== ====== ======

'/>"/>

SOURCE Patient Safety Technologies, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. California Cancer Specialists Medical Group, Inc. Opens Outpatient Cancer Center in South Pasadena, Calif., With Renowned Medical Staff, State-of-the-Art Technology
2. Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs)
3. Inpatient Management, Inc. and Reid Hospital Achieve Performance Improvement and Cost Savings
4. Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer
5. Genome of Leukemia Patient Reveals Common Mutations
6. Digital mammography plus digital breast tomosynthesis may decrease patient recall rates
7. Happy Employees Lead to Healthier Patients
8. Londons Barts Hospital Selects Varian Equipment to Offer Advanced Radiotherapy to More Cancer Patients
9. Lilly Broadens Income Eligibility for Patient Assistance Programs
10. Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir
11. Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis